The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
EvansT.R., PentheroudakisG., PaulJ.A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophagogastric adenocarcinoma. Ann Oncol.2002; 13(9): 1469–1478.
2.
CorporaalS., SmitW.M., RusselM.G., van der PalenJ., BootH., LegdeurM.C.Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. Neth J Med.2006; 64(5): 141–146.
3.
CunninghamD., StarlingN., RaoS.Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med.2008; 358(1): 36–46.
4.
ChoE.K., LeeW.K., ImS.A.A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. Oncology.2005; 68(4-6): 333–340.
5.
ParkS.H., ParkY.H., LeeJ.N.Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer.2006; 106(2): 361–365.
6.
VillmanK., OhdJ.F., LidbrinkE.A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. Eur J Cancer.2007; 43(7): 1153–1160.
7.
StarlingN., OkinesA., CunninghamD.A phase II trial of preoperative chemotherapy with epirubicin, cisplatin, and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer.2009; 100(11): 1725–1730.
8.
OkinesA.F., NormanA.R., McCloudP., KangY.K., CunninghamD.Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol.2009; 20(9): 1529–1534.
KrisM.G., HeskethP.J., SomerfieldMR; American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
KrisM.G., GrallaR.J., ClarkR.A.Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol.1985; 3(10): 1379–1384.
16.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
17.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50(2): 147–158.
18.
KintzelP.E.Anticancer drug-induced kidney disorders. Drug Saf.2001; 24(1): 19–38.
ZanottiK.M., MarkhamM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf.2001; 24(10): 767–779.
21.
SmithT.J., KhatcheressianJ., LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
24.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–402.
25.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
26.
MarounJ.A., AnthonyL.B., BlaisN.Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol.2007; 14(1): 13–20.
27.
BensonABIII, AjaniJ.A., CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22(14): 2918–2926.
28.
GressettS.M., StanfordB.L., HardwickeF.Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract.2006; 12(3): 131–141.
29.
MortimerJ.E., LaumanM.K., TanB.Pyridoxine treatment and prevention of hand-foot syndrome in patients receiving capecitabine. J Oncol Pharm Pract.2003; 9(4): 161–166.
30.
SumpterK., Harper-WynneC., CunninghamD.Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer.2005; 92(11): 1976–1983.
31.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
32.
Xeloda [package insert].South San Francisco, CA: Genentech USA Inc; 2009.
33.
DobbsN.A., TwelvesC.J., GregoryW., CruickshankaC., RichardsM.A., RubensR.D.Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Eur J Cancer.2003; 39(5): 580–586.
34.
FloydJ., MirzaI., SachsB., PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
